文献速递肿瘤 PET/CT

89Zr-帕博利珠单抗PET/CT在晚期非小细胞肺癌患者中的研究

Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer.
PubMed 文献 · J Nucl Med · 2021-07-16

该研究纳入12例适合帕博利珠单抗单药治疗的晚期NSCLC患者,进行89Zr-帕博利珠单抗PET/CT显像,评估示踪剂安全性、肿瘤摄取与PD-1/PD-L1表达及疗效的关系。结果显示示踪剂注射安全,仅1例3级不良事件;肿瘤摄取在缓解患者中数值更高但无统计学意义,且与PD-L1或PD-1免疫组化无显著相关性。

要点

  • 89Zr-帕博利珠单抗PET/CT在12例NSCLC患者中安全,仅1例3级肌痛。
  • 72个肿瘤病灶中47.2%可见示踪剂摄取,患者间及病灶内异质性明显。
  • 缓解患者肿瘤摄取中位SUVpeak 11.4 vs 无缓解5.7,P=0.066,未达统计学显著。

核心结论

  • 89Zr-帕博利珠单抗注射安全,12例中仅1例3级不良事件可能免疫相关。
  • 89Zr-帕博利珠单抗肿瘤摄取在帕博利珠单抗治疗缓解患者中更高,但与PD-L1或PD-1免疫组化无显著相关性。

研究设计与样本

  • 纳入适合帕博利珠单抗单药一线或后线治疗的NSCLC患者,接受2次89Zr-帕博利珠单抗注射(一次无前驱剂量,一次在注射示踪剂前给予200 mg帕博利珠单抗),示踪剂注射后最多行4次PET/CT扫描。
  • 影像采集后患者每3周接受200 mg帕博利珠单抗治疗,视觉评估和定量肿瘤摄取及示踪剂生物分布,并与PD-1/PD-L1表达及疗效进行相关性分析。

主要发现

  • 共纳入12例NSCLC患者,1例在示踪剂注射后出现3级肌痛。
  • 89Zr-帕博利珠单抗见于血池、肝脏和脾脏。
  • 72个长轴直径≥20 mm的肿瘤病灶中47.2%可见示踪剂摄取,患者内和患者间观察到显著摄取异质性。
  • 缓解患者(n=3)肿瘤摄取高于无缓解患者(n=9),中位SUVpeak 11.4 vs. 5.7,P=0.066,但无统计学意义。
  • 肿瘤摄取与PD-L1或PD-1免疫组化无显著相关性。

关键数值与推荐

  • 肿瘤病灶长轴直径≥20 mm共72个,其中47.2%可见89Zr-帕博利珠单抗摄取。
  • 缓解患者中位SUVpeak为11.4,无缓解患者为5.7,P=0.066。

临床怎么用

  • 89Zr-帕博利珠单抗PET/CT显像安全可行,但本研究样本量小,肿瘤摄取与疗效的相关性未达统计学显著,尚不能用于临床筛选帕博利珠单抗获益患者。
  • 肿瘤摄取与PD-L1/PD-1免疫组化无显著相关,提示免疫组化可能不足以完全反映体内药物分布。

局限性

  • 样本量小(12例),缓解组仅3例,统计效能有限。
  • 肿瘤摄取与疗效的相关性未达统计学显著(P=0.066)。
  • 单中心研究,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However, not all patients respond to therapy. Better understanding of in vivo drug behavior may help in the selection of patients who will benefit the most. Methods: NSCLC patients eligible for pembrolizumab monotherapy as first- or later-line therapy were enrolled. Patients received 2 injections of 89Zr-pembrolizumab, 1 without a preceding dose of pembrolizumab and 1 with a preceding dose of 200 mg of pembrolizumab, directly before tracer injection. Up to 4 PET/CT scans were obtained after tracer injection. After imaging acquisition, patients were treated with 200 mg of pembrolizumab every 3 wk. Tumor uptake and tracer biodistribution were visually assessed and quantified as the SUV. Tumor tracer uptake was correlated with PD-1 and PD-L1 expression and response to pembrolizumab treatment. Results: Twelve NSCLC patients were included. One patient experienced grade 3 myalgia after tracer injection. 89Zr-pembrolizumab was observed in the blood pool, liver, and spleen. Tracer uptake was visualized in 47.2% of 72 tumor lesions measuring ΒΧΡ20 mm in the long-axis diameter, and substantial uptake heterogeneity was observed within and between patients. Uptake was higher in patients with a response to pembrolizumab treatment (n = 3) than in patients without a response (n = 9), although this finding was not statistically significant (median SUVpeak, 11.4 vs. 5.7; P = 0.066). No significant correlations were found with PD-L1 or PD-1 immunohistochemistry. Conclusion:89Zr-pembrolizumab injection was safe, with only 1 grade 3 adverse event-possibly immune-related-in 12 patients. 89Zr-pembrolizumab tumor uptake was higher in patients with a response to pembrolizumab treatment but did not correlate with PD-L1 or PD-1 immunohistochemistry.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Niemeijer AN, Oprea-Lager DE, Huisman MC, et al. Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2021. PMID: 34272316. doi:10.2967/jnumed.121.261926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。